carcinoma: Urothelial carcinoma.

Description Usage Format References

Description

Survival data from a trial comparing chemotherapy versus atezolizumab in the treatment of Urothelial carcinoma.

Usage

1

Format

A data frame with 625 observations (316 in the atezolizumab group and 309 chemotherapy group) with the following 3 columns:

time

the observed follow-up times in days.

status

the event indicators, 0=right censored, 1= event.

group

the group labels, 1 = atezolizumab, 2 = chemotherapy.

References

Powles T, Dura?n I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018; 391: 748-757.


matan-schles/KONPSURV documentation built on Jan. 4, 2022, 6:21 p.m.